What are the implications of elevated iron saturation, also known as Hyperferritinemia or Iron overload?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Elevated iron saturation should be treated with phlebotomy to remove excess iron and prevent organ damage, as recommended by the EASL clinical practice guidelines for HFE hemochromatosis 1. The goal of treatment is to reduce iron levels to normal, thereby preventing complications such as liver cirrhosis, diabetes, arthropathy, hypogonadism, and porphyria cutanea tarda.

  • Phlebotomy should be carried out by removing 400–500 ml of blood (200–250 mg iron) weekly or every two weeks, with adequate hydration before and after treatment, and avoidance of vigorous physical activity for 24 h after phlebotomy 1.
  • Before initiating phlebotomy, patients should be assessed for complications including diabetes mellitus, joint disease, endocrine deficiency (hypothyroidism), cardiac disease, porphyria cutanea tarda, and osteoporosis 1.
  • Additionally, patients with elevated iron saturation should be monitored annually, and treatment should be instituted when ferritin levels rise above normal 1.
  • It is also important to manage any complications that may arise, regardless of whether or not they are directly related to the iron overload, and to immunize patients against hepatitis A and B while they are iron overloaded 1.

From the FDA Drug Label

Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. The answer to elevated iron saturation is that deferasirox is indicated for the treatment of chronic iron overload.

  • Key points:
    • Deferasirox is an iron chelator.
    • It is used to treat chronic iron overload due to blood transfusions.
    • The treatment is for patients 2 years of age and older 2

From the Research

Elevated Iron Saturation

Elevated iron saturation can be caused by various conditions, including hereditary hemochromatosis and secondary hemochromatosis.

  • Hereditary hemochromatosis is a genetic disorder that leads to increased iron absorption, resulting in iron overload and potential organ damage 3.
  • Secondary hemochromatosis, on the other hand, is caused by acquired anemia, such as thalassemia, and is characterized by ineffective erythropoiesis leading to increased duodenal uptake of iron 4.

Treatment Options

Treatment options for elevated iron saturation depend on the underlying cause.

  • For hereditary hemochromatosis, phlebotomy is often the standard treatment, but iron chelators such as deferasirox can be used as an alternative, especially in patients who are intolerant or refractory to phlebotomy 5, 6.
  • For secondary hemochromatosis, iron chelators such as deferasirox are often used to remove excess iron, as phlebotomy is not a suitable option 4.
  • Other treatment options, such as erythrocytapheresis, may also be considered, especially in patients with hereditary hemochromatosis 6.

Diagnostic Testing

Diagnostic testing for elevated iron saturation typically involves measuring serum ferritin and transferrin-iron saturation levels.

  • Genetic testing for HFE mutations, such as C282Y and H63D, may also be performed to confirm a diagnosis of hereditary hemochromatosis 3.
  • Magnetic resonance imaging or liver biopsy may be used to assess iron content and liver damage in patients with suspected iron overload 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Iron overload disorders.

Hepatology communications, 2022

Research

The treatment of secondary hemochromatosis.

Deutsches Arzteblatt international, 2009

Research

How we manage patients with hereditary haemochromatosis.

British journal of haematology, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.